Background
==========

T2\* multislice multiecho cardiac magnetic resonance (CMR) allows quantification of the segmental distribution of myocardial iron overload (MIO). This study aimed to determine if a preferential pattern of MIO was preserved between two CMR scans in thalassemia major (TM) patients.

Methods
=======

Among the 812 TM patients with a CMR follow-up (FU) study at 18±3 months, we selected 259 patients with significant MIO at baseline (global heart T2\* \<26 ms). Three short-axis views of the left ventricle were acquired and analyzed using a 16-segment standardized model. The T2\* value on each segment was calculated, as well as the global value. Four main circumferential regions (anterior, septal, inferior and lateral) were defined.

Results
=======

The selected patient population was divided into two groups: severe (N=80, global T2\* \< 10 ms) and mild-moderate MIO (N=179, global T2\* 10-26 ms).

For each group, there was a significant improvement in the global heart as well as in regional T2\* values (P\<0.0001 for all the pairwise comparisons).

For the whole patient population as well as for both two groups, at basal the mean T2\* value over the anterior region was significantly lower than the mean T2\* values over the other regions and the mean T2\* over the inferior region was significantly lower than the T2\* values over the septal and the lateral regions. The same pattern was present at the FU, with a little difference for patients with mild-moderate MIO (see figure).
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Conclusions
===========

A preferential pattern of iron store in anterior and inferior regions was present at both basal and FU CMRs, with an increment of T2\* values at FU due to a basal CMR-guided chelation therapy. The anterior region seems to be the region in which the iron accumulates first and is removed later. Our data confirm the segmental T2\* cardiac MR approach useful for identifying early iron deposit and for tailoring chelation therapy.
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